Skip to main content
. 2019 Jan 28;20(3):541. doi: 10.3390/ijms20030541

Figure 6.

Figure 6

Treatment outcomes during daily intradermal applications of 0.5 mm pilocarpine nanofiber mats versus systemic pilocarpine in an acute in vivo SG model of SG hypofunction. (A) Schematic drawing of the in vivo SG hypofunction model to induce acute dry mouth for the daily proposed intradermal treatment with pilocarpine nanofiber mat and conventional systemic administration. (B) Saliva secretion rate during the first 24 h after daily intradermal application of 0.5 mm-diameter pilocarpine nanofiber mats (PNM) when compared to systemic pilocarpine (SP). (C) Salivary gland weight remained unchanged after intradermal application of 0.5 mm pilocarpine nanofiber mats. Error bars represent SEM from n = 4–5. * p ˂ 0.05 when compared to irradiated group with systemic pilocarpine only (SP, which represents the positive CTL). IR: irradiated (negative CTL). nonIR: non-irradiated control group. SGs: salivary glands.